Sarepta appoints Henri Termeer advisor to the company
This article was originally published in Scrip
Executive Summary
Sarepta Therapeutics, a developer of innovative RNA-targeted therapeutics, has named former CEO of Genzyme Henri Termeer a key advisor to the company. Mr Termeer is the former chair, president and CEO of Genzyme, where he served for nearly three decades before retiring in 2011 following the acquisition of Genzyme by Sanofi in a transaction valued at more than $20bn.
You may also be interested in...
Six New Molecules By 2030 – J&J’s Neuroscience Strategy
Can neuroscience be precise? Peter Fang, worldwide VP of neuroscience, explains J&J's approach to precision medicine in Alzheimer’s disease, depression and other neurological conditions.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.